Clinical trials: Symptoms and Signs
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233881
- Testing
- Atrovent® - inhalets
- Volunteers
- 4,222 people
- Sponsor
- Boehringer Ingelheim
Fatigue, Locally Advanced or Metastatic Breast Cancer
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
Primary objective: To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale.
- Trial name
- NCT05212701
- Testing
- Reparixin
- Where
- 20 sites in United States, Germany and 1 more
- Sponsor
- Dompé Farmaceutici S.p.A
Rheumatic Diseases, Arthralgia
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
- Conditions
- Rheumatic Diseases, Arthralgia, Myalgias/Myopathy, Lumbago
- Trial name
- 157 (NCT00922428)
- Volunteers
- 1,389 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary…
- Trial name
- NCT00615992
- Testing
- Tiotropium
- Where
- 73 sites in Austria
- Volunteers
- 754 people
- Sponsor
- Boehringer Ingelheim
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT05645744
- Testing
- Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Chronic Kidney Disease, Type 2 Diabetes
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to…
- Trial name
- NCT01500798
- Testing
- 20 mg bardoxolone methyl
- Volunteers
- 18 people
- Sponsor
- Biogen
Shock, Hemorrhagic, Shock, Traumatic
Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients
MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia.
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Acidosis, Lactic
- Trial name
- NCT01004198
- Testing
- MP4OX, Ringers Lactate solution
- Where
- 13 sites in France, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- Sangart
Breast Cancer, Hormone Receptor Positive Tumor
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INGE-B (NCT02894398)
- Testing
- Palbociclib, Letrozole, Anastrozole
- Where
- 70 sites in Germany
- Volunteers
- 388 people
- Sponsor
- iOMEDICO AG
Knee Injuries and Disorders, Shoulder Disease
C Scope Visualization System Prospective Study
Evaluation of the performance and safety of the C Scope Visualization System
- Conditions
- Knee Injuries and Disorders, Shoulder Disease, Shoulder Injuries
- Trial name
- NCT05153863
- Testing
- C Scope Visualization System
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- CIT Ortho
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Premenstrual Syndrome, Mastodynia
Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS
The purpose of this study is to proof the efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 film-coated tablets in patients suffering from cyclic mastodynia and PMS (pre menstrual syndrome).
- Trial name
- NCT01870687
- Testing
- 20mg VAC BNO 1095 FCT
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bionorica SE
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic…
- Trial name
- NCT07819071
- Testing
- Tested Emollient RV5258A, tacrolimus 0.1%
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Prostatic Neoplasms, Metastases, Neoplasm
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
- Trial name
- NCT00055471
- Testing
- ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.